Top

Published in:

01-07-2014 | Research

WT1 Overexpression Affecting Clinical Outcome in Non-Hodgkin Lymphomas and Adult Acute Lymphoblastic Leukemia

Authors: Zsófia Ujj, Gergely Buglyó, Miklós Udvardy, György Vargha, Sándor Biró, László Rejtő

Published in: Pathology & Oncology Research | Issue 3/2014

Abstract

The Wilms tumor 1 (WT1) gene has a complex role as a transcriptional regulator, acting as tumor suppressor or oncogene in different malignancies. The prognostic role of its overexpression has been well-studied in leukemias, especially acute myeloid leukemia (AML), but not in lymphomas. For the first time to our knowledge, we present a study demonstrating the correlation of WT1 expression and survival in various non-Hodgkin lymphomas. We also studied the prognostic implications of WT1 overexpression in adult acute lymphoblastic leukemia (ALL). In our sample of 53 patients—25 with diffuse large B-cell lymphoma (DLBCL), 8 with mantle cell lymphoma (MCL), 9 with peripheral T-cell lymphoma (PTCL), 2 with Burkitt’s lymphoma, 2 with mucosa-associated lymphoid tissue (MALT) lymphoma, and 7 with B-cell ALL—, we measured WT1 mRNA from blood samples by quantitative RT-PCR, and divided the patients into subgroups based on the level of expression. Kaplan–Meier survival curves were drawn and compared using the logrank test. In the sample of DLBCL patients, the difference in overall and disease-free survival between WT1-positive and negative subgroups was significant (p = 0.0475 and p = 0.0004, respectively), and in a few observed cases, a sudden increase in WT1 expression signified a relapse soon followed by death. Disease-free survival curves in MCL and ALL were similarly suggestive of a potential role played by WT1. In PTCL, though WT1-positivity was detected in 4 out of 9 cases, it did not seem to affect survival. The few cases of MALT and Burkitt’s lymphoma all proved to be WT1-negative.

Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH (1990) Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell 60(3):509–520PubMedCrossRef

Hohenstein P, Hastie ND (2006) The many facets of the Wilms’ tumour gene, WT1. Hum Mol Genet 15:R196–R201PubMedCrossRef

Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE (1991) Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci U S A 88(21):9618–9622PubMedCentralPubMedCrossRef

Dallosso AR, Hancock AL, Brown KW, Williams AC, Jackson S, Malik K (2004) Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms’ tumours. Hum Mol Genet 13:405–415PubMedCrossRef

Hastie ND (2001) Life, sex, and WT1 isoforms – three amino acids can make all the difference. Cell 106:391–394PubMedCrossRef

Morrison AA, Viney RL, Ladomery MR (2008) The post-transcriptional roles of WT1, a multifunctional zinc-finger protein. Biochim Biophys Acta 1785:55–62PubMed

Miwa H, Beran M, Aunders GF (1992) Expression of the Wilms tumor gene (WT1) in human leukemias. Leukemia 6:405–409PubMed

Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E, Hoelzer D (1997) High levels of Wilms’ tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 90:1217–1225PubMed

Glienke W, Maute L, Koehl U, Esser R, Milz E, Bergmann L (2007) Effective treatment of leukemic cell lines with wt1 siRNA. Leukemia 21:2164–2170PubMedCrossRef

10.

Candoni A, Toffoletti E, Gallina R, Simeone E, Chiozzotto M, Volpetti S, Fanin R (2011) Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia. Clin Transplant 25(2):308–316PubMedCrossRef

11.

Nowakowska-Kopera A, Sacha T, Florek I, Zawada M, Czekalska S, Skotnicki AB (2009) Wilms’ tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia. Leuk Lymphoma 50(8):1326–1332PubMedCrossRef

12.

Boublikova L, Kalinova M, Ryan J, Quinn F, O’Marcaigh A, Smith O, Browne P, Stary J, McCann SR, Trka J, Lawler M (2006) Wilms’ tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 20(2):254–263PubMedCrossRef

13.

Busse A, Gökbuget N, Siehl JM, Hoelzer D, Schwartz S, Rietz A, Thiel E, Keilholz U (2009) Wilms’ tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome. Ann Hematol 88(12):1199–1205PubMedCrossRef

14.

Sadek HA, El-Metnawey WH, Shaheen IA, Korshied MM, Mohamed AS (2011) Quantitative assessment of Wilms tumor 1 (WT1) gene transcripts in Egyptian acute lymphoblastic leukemia patients. J Investig Med 59(8):1258–1262PubMed

15.

Drakos E, Rassidakis GZ, Tsioli P, Lai R, Jones D, Medeiros LJ (2005) Differential expression of WT1 gene product in non-Hodgkin lymphomas. Appl Immunohistochem Mol Morphol 13:132–137PubMedCrossRef

16.

Mazrouei S, Ziaei A, Tanhaee AP, Keyhanian K, Esmaeili M, Baradaran A, Salehi M (2012) Apoptosis inhibition or inflammation: the role of NAIP protein expression in Hodgkin and non-Hodgkin lymphomas compared to non-neoplastic lymph node. J Inflamm Lond 9:4PubMedCentralPubMedCrossRef

17.

Hoelzer D, Thiel E, Löffler H, Bodenstein H, Plaumann L, Büchner T, Urbanitz D, Koch P, Heimpel H, Engelhardt R (1983) Recruiting patients and results of a preliminary study on the therapy of acute lymphatic leukemia and acute undifferentiated leukemia in adults. Onkologie 6(4):170–174PubMedCrossRef

18.

Wang YF, Yang YL, Gao ZF, Zhou CJ, Gregg X, Shi YF, Wang J, Yang XF, Ke XY (2012) Clinical and laboratory characteristics of systemic anaplastic large cell lymphoma in Chinese patients. J Hematol Oncol 5:38PubMedCentralPubMedCrossRef

19.

Vadasz Z, Shasha-Lavsky H, Nov Y, Bejar J, Lurie M, Tadmor T, Attias D (2012) Wilms’ tumor gene 1: a possible new proangiogenic factor in hodgkin lymphoma. Appl Immunohistochem Mol Morphol. doi:10.1097/PAI.0b013e318259852a

20.

Gurbuxani S (2007) WT1 expression in myelodysplastic syndrome. Leuk Lymphoma 48(3):456–457PubMedCrossRef

21.

Perotti D, Mondini P, Giardini R, Ferrari A, Massimino M, Gambirasio F, Pierotti MA, Fossati-Bellani F, Radice P (1998) No evidence of WT1 involvement in a Burkitt’s lymphoma in a patient with Denys-Drash syndrome. Ann Oncol 9(6):627–631PubMedCrossRef

22.

Tosello V, Mansour MR, Barnes K, Paganin M, Sulis ML, Jenkinson S, Allen CG, Gale RG, Linch DC, Palomero T, Real P, Murty V, Yao X, Richards SM, Goldstone A, Rowe J, Basso G, Wiernik PH, Paietta E, Pieters R, Horstmann M, Meijerink JPP, Ferrando AA (2009) WT1 mutations in T-ALL. Blood 114(5):1038–1045PubMedCentralPubMedCrossRef

23.

Heesch S, Goekbuget N, Stroux A, Tanchez JO, Schlee C, Burmeister T, Schwartz S, Blau O, Keilholz U, Busse A, Hoelzer D, Thiel E, Hofmann WK, Baldus CD (2010) Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. Haematologica 95(6):942–949PubMedCentralPubMedCrossRef

24.

Oka Y, Tsuboi A, Oji Y, Kawase I, Sugiyama H (2008) WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 20(2):211–220PubMedCrossRef

Title: WT1 Overexpression Affecting Clinical Outcome in Non-Hodgkin Lymphomas and Adult Acute Lymphoblastic Leukemia
Authors: Zsófia Ujj
Gergely Buglyó
Miklós Udvardy
György Vargha
Sándor Biró
László Rejtő
Publication date: 01-07-2014
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 3/2014
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-013-9729-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Screening of Hub Genes and Pathways in Colorectal Cancer with Microarray Technology

Low Prevalence of K-RAS, EGF-R and BRAF Mutations in Sinonasal Adenocarcinomas. Implications for Anti-EGFR Treatments

Tumor-Associated Macrophages are Correlated with Tamoxifen Resistance in the Postmenopausal Breast Cancer Patients

Transforming Growth Factor-Beta Signaling Leads to uPA/PAI-1 Activation and Metastasis: A Study on Human Breast Cancer Tissues

Salivary Proteomic Analysis of Diabetic Patients for Possible Oral Squamous Cell Carcinoma Biomarkers

The Expression of p66Shc Protein in Benign, Premalignant, and Malignant Gastrointestinal Lesions

Keynote webinar | Spotlight on antibody–drug conjugates in cancer